Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma

American Journal of Respiratory and Critical Care Medicine

Volumn 173, Issue 10, 2006, Pages 1155-1160

  Scherpereel, Arnaud ^a   Grigoriu, Bogdan ^b   Conti, Massimo ^b   Gey, Thomas ^b   Grégoire, Marc ^b   Copin, Marie Christine ^b   Devos, Patrick ^b   Chahine, Bachar ^b   Porte, Henri ^b   Lassalle, Philippe ^b  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b NONE

Author keywords

Diagnosis; Marker; Neoplasm; Pleural disease

Indexed keywords

MESOTHELIN; OSTEOPONTIN; PEPTIDE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PLEURA FLUID; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC;

AGED; ANALYSIS OF VARIANCE; AREA UNDER CURVE; ASBESTOSIS; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MESOTHELIOMA; MIDDLE AGED; NEOPLASM STAGING; OSTEOPONTIN; PLEURAL EFFUSION, MALIGNANT; PLEURAL NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SIALOGLYCOPROTEINS; SOLUBILITY; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 33646587019     PISSN: 1073449X     EISSN: 1073449X     Source Type: Journal    
DOI: 10.1164/rccm.200511-1789OC     Document Type: Article

References (34)

1. Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet 2005;366:397-408.
2. Pass HI, Vogelzang N, Hahn S, Carbone M. Malignant pleural mesothelioma. Curr Probl Cancer 2004;28:93-174.
3. Ordonez NG. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma. Am J Surg Pathol 2003;27:1031-1051.
4. Hegmans JPJJ, Hemmes A, Aerts JG, Hoogsteden HC, Lambrecht BN. Immunotherapy of murine malignant mesothelioma using tumor lysate-pulsed dendritic cells. Am J Respir Crit Care Med 2005;171:1168-1177.
5. Ebstein F, Sapede C, Royer P-J, Marcq M, Ligeza-Poisson C, Barbieux I, Cellerin L, Dabouis G, Gregoire M. Cytotoxic T cell responses against mesothelioma by apoptotic cell-pulsed dendritic cells. Am J Respir Crit Care Med 2004;169:1322-1330.
6. Sterman DH, Recio A, Vachani A, Sun J, Cheung L, DeLong P, Amin KM, Litzky LA, Wilson JM, Kaiser LR, et al. Long-term follow-up of patients with malignant pleural mesothelioma receiving high-dose adenovirus herpes simplex thymidine kinase/ganciclovir suicide gene therapy. Clin Cancer Res 2005;11:7444-7453.
7. Cao XX, Mohuiddin I, Ece F, McConkey DJ, Smythe WR. Histone Deacetylase Inhibitor Downregulation of bcl-xl gene expression leads to apoptotic cell death in mesothelioma. Am J Respir Cell Mol Biol 2001;25:562-568.
8. Rump A, Morikawa Y, Tanaka M, Minami S, Umesaki N, Takeuchi M, Miyajima A. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem 2004;279:9190-9198.
9. Chang K, Pai LH, Pass H, Pogrebniak HW, Tsao MS, Pastan I, Willingham MC. Monoclonal antibody K1 reacts with epithelial mesothelioma but not with lung adenocarcinoma. Am J Surg Pathol 1992;16:259-268.
10. Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA 1996;93:136-140.
11. Ordonez NG. Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod Pathol 2003;16:192-197.
12. Hornick JL, Lauwers GY, Odze RD. Immunohistochemistry can help distinguish metastatic pancreatic adenocarcinomas from bile duct adenomas and hamartomas of the liver. Am J Surg Pathol 2005;29:381-389.
13. Ordonez NG. Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol 2003;27:1418-1428.
14. Watanabe H, Okada G, Ohtsubo K, Yamaguchi Y, Mouri H, Motoo Y, Wakabayashi T, Sawabu N. Expression of mesothelin mRNA in pure pancreatic juice from patients with pancreatic carcinoma, intraductal papillary mucinous neoplasm of the pancreas, and chronic pancreatitis. Pancreas 2005;30:349-354.
15. Gilks CB, Vanderhyden BC, Zhu S, van de Rijn M, Longacre TA. Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling. Gynecol Oncol 2005;96:684-694.
16. Scholler N, Fu N, Yang Y, Ye Z, Goodman GE, Hellstrom KE, Hellstrom I. Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc Natl Acad Sci USA 1999;96:11531-11536.
17. Drapkin R, Crum CP, Hecht JL. Expression of candidate tumor markers in ovarian carcinoma and benign ovary: evidence for a link between epithelial phenotype and neoplasia. Hum Pathol 2004;35:1014-1021.
18. Frierson HF Jr, Moskaluk CA, Powell SM, Zhang H, Cerilli LA, Stoler MH, Cathro H, Hampton GM. Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas. Hum Pathol 2003;34:605-609.
19. Liebig B, Brabletz T, Staege MS, Wulfanger J, Riemann D, Burdach S, Ballhausen WG. Forced expression of deltaN-TCF-1B in colon cancer derived cell lines is accompanied by the induction of CEACAM5/6 and mesothelin. Cancer Lett 2005;223:159-167.
20. Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, Vasa P, Ladd C, Beheshti J, Bueno R, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA 2001;98:13790-13795.
21. Hassan R, Bera T, Pastan I. Mesothelin: a new target for immunotherapy. Clin Cancer Res 2004;10:3937-3942.
22. Robinson BW, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N, Winzell P, Hellstrom KE, Hellstrom I. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003;362:1612-1616.
23. McIntosh MW, Drescher C, Karlan B, Scholler N, Urban N, Hellstrom KE, Hellstrom I. Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. Gynecol Oncol 2004;95:9-15.
24. American Thoracic Society. Diagnosis and initial management of nonmalignant diseases related to asbestos. Am J Respir Crit Care Med 2004;170:691-715.
25. Conover WJ, Iman RL. Analysis of covariance using the rank transformation. Biometrics 1982;38:715-724.
26. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983;148:839-843.
27. Cullen MR. Serum osteopontin levels: is it time to screen asbestosexposed workers for pleural mesothelioma? N Engl J Med 2005;353:1617-1618.
28. Hillerdal G, Lindqvist U, Engstrom-Laurent A. Hyaluronan in pleural effusions and in serum. Cancer 1991;67:2410-2414.
29. Pass H, Wolaniuk D, Wali A, Thiel A, Hellstrom I, Hellstrom K, Sardesai N. Soluble mesothelin related peptides: a potential biomarker for malignant pleural mesothelioma [abstract]. J Clin Oncol 2005;23:9532.
30. Robinson BW, Robinson C, Lake RA. Localised spontaneous regression in mesothelioma: possible immunological mechanism. Lung Cancer 2001;32:197-201.
31. Jain S, Bhojwani AG, Mellon JK. Improving the utility of prostate specific antigen (PSA) in the diagnosis of prostate cancer: the use of PSA derivatives and novel markers. Postgrad Med J 2002;78:646-650.
32. Ordonez NG. The diagnostic utility of immunohistochemistry in distinguishing between mesothelioma and renal cell carcinoma: a comparative study. Hum Pathol 2004;35:697-710.
33. Pass HI, Lott D, Lonardo F, Harbut M, Liu Z, Tang N, Carbone M, Webb C, Wali A. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 2005;353:1564-1573.
34. Rittling SR, Chambers AF. Role of osteopontin in tumour progression. Br J Cancer 2004;90:1877-1881.